The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors

World Allergy Organization Journal

Werner J Pichler¹ 

[1] Division of Allergology, Clinic for Rheumatology and Clinical Immunology/Allergology, University of Berne, Berne, Switzerland

关键词: T cells;    T-cell receptor;    prohapten;    hapten;    drug hypersensitivity;    p-i concept;   

Others  :  824539
DOI  :  10.1097/WOX.0b013e3181778282

 received in 2007-12-31, accepted in 2008-03-07,  发布年份 2008

【 摘 要 】

The immune response in drug hypersensitivity is normally explained by the hapten hypothesis. It postulates that drugs with a molecular weight of less than 1000 D are too small to cause an immune response per se. However, if a chemically reactive drug or drug metabolite binds covalently to a protein and thus forms a so-called hapten-carrier complex, this modified protein can induce an immune response. This concept has recently been supplemented by the p-i concept (or pharmacological interaction with immune receptors), which postulates that some drugs that lack hapten characteristics can bind directly and reversibly (noncovalently) to immune receptors and thereby stimulate the cells. For example, a certain drug may bind to a particular T-cell receptor, and this binding suffices to stimulate the T cell to secrete cytokines, to proliferate, and to exert cytotoxicity. The p-i concept has major implications for our understanding of drug interaction with the specific immune system and for drug hypersensitivity reactions. It is based on extensive investigations of T-cell clones reacting with the drug and recently of hybridoma cells transfected with the drug-specific T-cell receptor for antigen (TCR). It is a highly specific interaction dependent on the expression of a TCR into which the drug can bind with sufficient affinity to cause signaling. Small modification of the drug structure may already abrogate reactivity. Stimulation of T cells occurs within minutes as revealed by rapid Ca⁺⁺ influx after drug addition to drug-specific T-cell clones or hybridoma cells, thus, before metabolism and processing can occur. As the immune system can only react in an immunologic way, the symptoms arising after drug stimulation of immune receptors imitate an immune response after recognition of a peptide antigen, although it is actually a pharmacological stimulation of some T cells via their TCRs. Clinically, the p-i concept could explain the sometimes rapid appearance of symptoms without previous sensitizations and the sometimes chaotic immune reaction of drug hypersensitivity with participation of different immune mechanisms while normal immune reactions to antigens are highly coordinated. Nevertheless, because the reactions lead to expansion of drug-reactive cells, many features such as skin test reactivity and stronger reactivity upon reexposure are identical to real immune reactions.

【 授权许可】

   
2008 World Allergy Organization; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Pichler WJ: Drug Hypersensitivity. 2007. Karger, Basel
• [2]Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK: Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000, 23:483-507.
• [3]Pichler WJ: Delayed drug hypersensitivity reactions. Ann Intern Med 2003, 139:683-693.
• [4]Manfredi M, Severino M, Testi S, Macchia D, Ermini G, Pichler WJ, Campi P: Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004, 113:155-160.
• [5]Gamerdinger K, Moulon C, Karp DR, Van Bergen J, Koning F, Wild D, et al.: A new type of metal recognition by human T cells: contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. J Exp Med 2003, 197:1345-1353.
• [6]Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU: Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur J Immunol 1997, 27:1303-1307.
• [7]Aiba S, Manome H, Nakagawa S, Mollah ZU, Mizuashi M, Ohtani T, et al.: p38 Mitogen-activated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene. J Invest Dermatol 2003, 120:390-399.
• [8]Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C: A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 2001, 166:3837-3845.
• [9]Sanderson JP, Naisbitt DJ, Farrell J, Ashby CA, Tucker MJ, Rieder MJ, et al.: Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 2007, 178:5533-5542.
• [10]Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3:196-200.
• [11]Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E: Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998, 19:133-141.
• [12]Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, et al.: Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003, 111:1393-1403.
• [13]Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, et al.: Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003, 63:732-741.
• [14]Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ: Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997, 100:136-141.
• [15]Crispe IN: Hepatic T cells and liver tolerance. Nat Rev Immunol 2003, 3:51-62.
• [16]Knowles SR, Uetrecht J, Shear NH: Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000, 356:1587-1591.
• [17]Bowen DG, Zen M, Holz L, Davis T, McCaughan GW, Bertolino P: The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004, 114:701-712.
• [18]Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, et al.: HLA-restricted, processing-and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998, 102:1591-1598.
• [19]Pichler WJ: Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002, 2:301-305.
• [20]Zanni MP, von Greyerz S, Hari Y, Schnyder B, Pichler WJ: Recognition of local anesthetics by alphabeta+ T cells. J Invest Dermatol 1999, 112:197-204.
• [21]Sieben S, Kawakubo Y, Al Masaoudi T, Merk HF, Blomeke B: Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J Allergy Clin Immunol 2002, 109:1005-1011.
• [22]Schmid D, Pichler WJ: T cell-mediated hypersensitivity to quinolones--mechanisms and crossreactivity. Clin Exp Allergy 2006, 36:59-69.
• [23]Schmid DA, Depta JP, Luthi M, Pichler WJ: Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds. Mol Pharmacol 2006, 70:356-365.
• [24]Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, et al.: Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000, 164:6647-6654.
• [25]Cribb AE, Spielberg SP: Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992, 51:522-526.
• [26]Burkhart C, von Greyerz S, Depta JP, Naisbitt DJ, Britschgi M, Park KB, Pichler WJ: Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001, 132:623-630.
• [27]Zanni MP, von Greyerz S, Schnyder B, Wendland T, Pichler WJ: Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific ab+ T cell clones. Int Immunol 1998, 10:507-515.
• [28]von Greyerz S, Bultemann G, Schnyder K, Burkhart C, Lotti B, Hari Y, Pichler WJ: Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. Int Immunol 2001, 13:877-885.
• [29]Burkhart C, Britschgi M, Strasser I, Depta JP, von Greyerz S, Barnaba V, Pichler WJ: Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides. Clin Exp Allergy 2002, 32:1635-1643.
• [30]Pichler WJ: Direct T-cell stimulations by drugs--bypassing the innate immune system. Toxicology 2005, 209:95-100.
• [31]Depta JP, Altznauer F, Gamerdinger K, Burkhart C, Weltzien HU, Pichler WJ: Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J Allergy Clin Immunol 2004, 113:519-527.
• [32]Vollmer J, Weltzien HU, Dormoy A, Pistoor F, Moulon C: Functional expression and analysis of a human HLA-DQ restricted, nickel-reactive T cell receptor in mouse hybridoma cells. J Investig Dermatol 1999, 113:175-181.
• [33]Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
• [34]Yang CWO, Hung SI, Juo CG, Lin YP, Fang WH, Lu IH, et al.: HLA-B*1502-bound peptides: implication for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007, 120:870-877.
• [35]Pichler WJ: Lessons from drug allergy: against dogmata. Curr Allergy Asthma Rep 2003, 3:1-3.
• [36]Christiansen C, Pichler WJ, Skotland T: Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations. Eur Radiol 2000, 10:1965-1975.
• [37]Pirmohamed M, Park BK: HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001, 1:311-316.
• [38]Hashimoto K, Yasukawa M, Tohyama M: Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol 2003, 3:255-260.
• [39]Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni MP, Schnyder B, et al.: T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001, 31:1398-1408.
• [40]Engler OB, Strasser I, Naisbitt DJ, Cerny A, Pichler WJ: A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitized individuals. Toxicology 2004, 197:47-56.
• [41]Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ: Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000, 30:847-855.
• [42]Posadas S, Posadas SJ, Pichler WJ: Delayed drug hypersensitivity reactions-new concepts. Clin Exp Allergy 2007, 37:989-999.
• [43]Schaerli P, Ebert L, Willimann K, Blaser A, Roos RS, Loetscher P, Moser B: A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med 2004, 199:1265-1275.
• [44]Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, Pichler WJ, Park BK: Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001, 133:295-305.
• [45]Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
• [46]Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005, 102:4134-4139.
• [47]Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, et al.: RegiSCAR Group. A marker for Stevens-Johnson syndrome...ethnicity matters. Pharmacogenomics J 2006, 6:265-268.
• [48]Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004, 101:4180-4185.